Tvardi’s TTI-101 overcomes palbociclib resistance in breast cancer models

By The Science Advisory Board staff writers
April 11, 2022

Tvardi Therapeutics will present preclinical data on April 11 at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans.

The data are from a study titled "Circulating [interleukin 6] IL-6, an early biomarker in [hormone receptor-positive] HR+, HER2-negative metastatic breast cancer patients progressing on CDK4/6 inhibitors" led by Dr. Khandan Keyomarsi at the University of Texas MD Anderson Cancer Center. The data will be presented by Nicole Kettner, PhD, a postdoctoral researcher in Keyomarsi's laboratory.

These data showed that Tavrdi's TTI-101, signal transducer and activator of transcription (STAT)-3 blocker, overcame palbociclib (CDK 4/6 inhibitor) resistance in HR+, HER2-negative metastatic murine breast cancer models through upregulation of IL-6/STAT3, according to a press release by the company.

Copyright © 2022

Last Updated 4/11/2022 2:46:03 PM